Cancer drug trial offers hope to halt deadly lung scarring
NCT ID NCT05515627
Summary
This early-stage study is testing whether atezolizumab, a drug approved for cancer, is safe and might help people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. It will involve about 24 adults aged 50-80 with IPF who can continue their standard medications. The main goal is to check for side effects, while also seeing if the drug can slow the disease by measuring lung function and scarring over 28 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Conditions
Explore the condition pages connected to this study.